<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To prevent <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD), <z:chebi fb="0" ids="168396">mycophenolate</z:chebi> mofetil (MMF) combined with calcineurin inhibitors have been used in allogeneic hematopoietic stem cell transplantation (allo-SCT) </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies commonly utilize MMF treatment until day 30 after allo-SCT </plain></SENT>
<SENT sid="2" pm="."><plain>However, the feasibility of continuous administration after day 30 has not been well evaluated </plain></SENT>
<SENT sid="3" pm="."><plain>We retrospectively assessed the safety and efficacy of extended drug administration </plain></SENT>
<SENT sid="4" pm="."><plain>Twenty-five patients ceased MMF at day 30 (group A); whereas, 16 patients (group B) received extended regimens depending on individual risk factors for GVHD </plain></SENT>
<SENT sid="5" pm="."><plain>No severe adverse events were observed in either group </plain></SENT>
<SENT sid="6" pm="."><plain>Although the cumulative incidence (CI) of grade I to IV GVHD at day 100 was comparable between the 2 groups, the CI of grade II to IV GVHD was less among group B (12.5%) compared with group A (42.3%) </plain></SENT>
<SENT sid="7" pm="."><plain>Extended MMF administration may be safe and beneficial as preemptive therapy to reduce the development of moderate-to-severe <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD </plain></SENT>
</text></document>